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Abstract
Background: Diagnosis of Periodic Fever, Aphthous stomatitis, Pharyngitis and Cervical Adenitis (PFAPA) syndrome
is currently based on the modified Marshall’s criteria, but no validated evidence based classification criteria for PFAPA
has been established so far.
Methods: A multistep process, based on the Delphi and Nominal Group Technique was conducted. After 2 rounds of
e-mail Delphi survey involving 21 experts in autoinflammation we obtained a list of variables that were discussed in an
International Consensus Conference. Variables reaching the 80% of consensus between participants were included in
the new classification criteria.
In the second phase the new classification criteria and the modified Marshall’s criteria were applied on a cohort of 80
pediatric PFAPA patients to compare their performance.
Results: The Delphi Survey was sent to 22 participants, 21 accepted to participate. Thirty variables were obtained from
the survey and have been discussed at the Consensus Conference. Through the Nominal Group Technique we obtained
a new set of classification criteria. These criteria were more restrictive in respect to the modified Marshall’s criteria when
applied on our cohort of patients.
Conclusion: Our work led us to identify a new set of classification criteria for PFAPA syndrome, but they resulted to be
too restrictive to be applied in daily clinical practice for the diagnosis of PFAPA.
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Background
Periodic Fever, Aphthous stomatitis, Pharyngitis and
Cervical Adenitis (PFAPA) syndrome is characterized by
regularly recurrent fever flares of early onset, accompanied
by pharyngitis, cervical lymphadenopathy and oral aph-
thous ulcers [1]. The diagnosis is currently based on the
modified Marshall’s criteria proposed in 1999 [2], but the
power of these criteria remains limited, and they show a
good sensitivity but a lack in specificity [3]. PFAPA is not a
well-defined disease and shows a clinical overlap with the
inherited periodic fevers, such as Familial Mediterranean
Fever, Tumor necrosis factor receptor-associated periodic
syndrome and Mevalonate kinase deficiency, for which
a causative gene is well established. These diseases often
require a more intensive therapeutic approach and have a
more severe course and long-term prognosis. Therefore
among those showing a PFAPA phenotype, it would be
important to identify patients at risk of carrying mutation
in genes associated with inherited periodic fever to avoid
unnecessary genetic testing [3]. Moreover, PFAPA shows a
clinical overlap with other infectious diseases, and more
specific criteria could help avoid prescriptions of unneces-
sary antibiotic therapies.
In 2008 we started an international collaborative effort,
aimed at developing new classification criteria based on
expert consensus and analysis of real patient data, to
identify a new set of classification criteria for PFAPA
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syndrome with higher specificity. This project was con-
ducted through several steps: 1) a preliminary Delphi sur-
vey among international pediatricians and rheumatologists;
2) a consensus conference of physicians with specific ex-
pertise in PFAPA to obtain a provisional new set of classifi-
cation criteria; 3) a preliminary evaluation of the new set of
criteria on a cohort of real PFAPA patients.
Methods
At first we proceeded to the creation of the classification
criteria by using the Delphi and Nominal Group Technique
[4]. We performed 2 rounds of e-mail Delphi survey involv-
ing 22 experts in autoinflammation to propose criteria for
the diagnosis of PFAPA: first the experts listed the most
relevant variables in their opinion for the diagnosis of
PFAPA, and the proposed variables were sorted in 8
categories; secondly, the experts had to validate categories
and individual items by groups of symptoms ranking the
criteria. Variables coming from this survey were discussed
in an International Conference that was held in Morges,
Switzerland, in November 2008, with 11 experts. By using
the Nominal Group technique, each variable included in
the list was discussed and included in the classification
criteria if a consensus of 80% was reached.
In the second phase we aimed to evaluate the new set
of criteria on a group of patients with a diagnosis of
PFAPA given at a specialized clinic for pediatric rheumatol-
ogy. Thus, we applied the new set of classification criteria
and the modified Marshall’s criteria on a cohort of 80
pediatric PFAPA patients from Lausanne (Switzerland) and
Genoa (Italy) pediatric rheumatology units to compare their
performance. For this study we selected all the patients with
a diagnosis of PFAPA validated by an experienced pediatric
rheumatologist (MH and MG), with complete information
on variables included in both sets of criteria.
Results
The Delphi Survey was sent to 22 participants, 21 ac-
cepted to participate, one didn’t respond.
Seventy-two different variables were obtained from the
first survey, and could be sorted in 8 different categories.
After the second Delphi, 6 categories reached consensus,
and 2 individual variables; the other categories and vari-
ables have been discussed at the Consensus Conference
(Table 1).
Through the Nominal Group Technique we obtained
a new set of classification.
criteria (Table 2).
Different version proposed for some variables were
ranked by participants to choose the most appropriated
one (e.g. duration of attacks: > 2 days, > 3 days, < 5 days,
3–6 days, max 5 days, or max 6 days).
Periodicity of the febrile episodes as well as the max-
imum interval between episodes were specified in the new
criteria, as well as the mandatory presence of at least one
sign during each episode or even 2 in most episodes.
In the new criteria age at disease onset was modified
in the new criteria at < 6 years instead of < 5 years, and
more detailed description of other causes that clinician
has to exclude were provided (other causes of recurrent
fever, infection and other immunodeficiency than cyclic
neutropenia). The new criteria specified that the pattern
of growth have to be linear. After discussion, response
to steroid was considered as supportive criteria and not
included in the new criteria.
Both the newly proposed PFAPA criteria and the
Marshall criteria were applied to a group of 80 PFAPA
patients followed in Lausanne and Genoa in order to test
their performance. The characteristics of patients included
in the analysis are shown in Table 3. The proportion of
boys and girls was 1:0.8. The median age at onset of PFAPA
was 1.9 years old, the median age at diagnosis was 4 years.
All patients presented at least one of the 3 cardinal
symptoms: aphthous stomatitis, pharyngitis, and cervical
adenitis. Abdominal pain was the most frequently asso-
ciated symptom, found in nearly 50% of the patients.
Only 41/80 patients (51%) fulfilled the new criteria. 31
patients were excluded because they didn’t meet one of
the classification criteria, 7 because of 2 criteria, and 1
because of 3 criteria. Application of both criterion 1 and
2 from the new criteria to our cohort resulted in the
exclusion of 36/39 (92%) patients.
Current modified Marshall criteria were met by 69/80
patients (86%). 7/80 didn’t fulfill the Marshall criteria be-
cause of the age at onset (after 5 years of age).
By comparing patients excluded by the two sets of cri-
teria, we noted that 6/80 patients (7,5%) were excluded
Table 1 Categories and variables reaching consensus during
both Delphi
Categories/variables Consensus (80%)
1. Recurrent fever attacks Delphi 1
Duration of attacks no
Regularity of fever attacks no
2. Constitutional symptoms Delphi 1
Actual criteriona no
New criterionb Delphi 2
3. Exclusion Delphi 1
Exclusion of autoinflammatory diseases Delphi 2
Exclusion of infections and related conditions Delphi 2
4. Age limitation for onset no
5. Well-being between episodes Delphi 2
6. Growth and development Delphi 2
7. Response to steroid treatment Delphi 2
8. Other no
aPhrased as in Marshall’s criteria; bmodify Marshall’s criteria
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from both. Table 2 provides the number of patients not
satisfying each criterion for both sets.
Discussion
Thanks to a collaborative effort made by clinicians in
the field of autoinflammatory diseases we developed a
provisional new set of classification criteria for PFAPA
disease based on experts’ opinion and we tested their
performance in a cohort of PFAPA patients. The new
criteria seem quite difficult to apply, since they need a
precise history that can’t always be provided by parents.
The characteristics of fever episodes provided in the new
criteria are probably too restrictive and excluded nearly
half of the patients. Conversely, the criterion “age at on-
set <6 years” seems better adapted and excluded only 1
patient [5]. There are not other substantial differences
between new criteria and modified Marshall’s criteria.
Globally, the new criteria were able to classify fewer pa-
tients as PFAPA in respect to the modified Marshall’s
criteria if applied on our cohort of patients. By using
these new criteria in clinical practice to diagnose PFAPA,
a significant number of patients would not be diagnosed,
and we consider them as not useful as diagnostic cri-
teria. On the other hand, since they are very restrictive,
these criteria probably would allow selecting a more
homogeneous group of patients; therefore they may be
suitable to select well-defined cohorts of patients for
clinical research. In fact, Marshall criteria have been
found to be poorly specific when tested in a population
in which different monogenic periodic fevers are present
[3]. This study presented some limitations and do not
resolve the classification dilemma of PFAPA patients for
Table 2 New set of PFAPA classification criteria and Modified Marshall’s classification criteria with number of patients that didn’t
fulfill each criterion
New classification criteria Patients excluded (N) Modified Marshall’s classification criteria Patients excluded (N)
1. Periodic Fever for at least 6 months:
a. Daily fever of at least 38.5 °C (axillar) for
2 to 7 days
b. At least 5 regularly recurring fever episodes
with maximum of 2 months interval between them
20 Regularly recurring fevers with an early
age onset (< 5 years of age)
7
2. Pharyngitis, cervical adenitis, oral aphthae: at least one
in every episode and at least 2 out of 3 in the majority
of episodes.
21 2. Constitutional symptoms in absence
of upper respiratory infection with at
least one of the following clinical signs:
• apthous stomatitis
• cervical lymphadenitis
• pharyngitis
0
3. Exclusion of other causes of recurrent fever
(clinical or by laboratory depending on history)
0 3. Exclusion of cyclic neutropenia 0
4. Exclusion of infections, immunodeficiency and
cyclic neutropenia
0
5. Disease onset before the age of 6 years 1
6. Full recovery between episodes 2 4. Completely asymptomatic interval
between episodes
2
7. Normal linear growth 4 5. Normal growth and development 3
Table 3 Characteristics of 80 PFAPA patients included in the
analysis
Characteristic
M/F 1.2
Age at onset (years) Median 1.9 (IQR 0.8–3.1)
Age at diagnosis (years) Median 4 (IQR 2.6–6)
Pharyngitis 88.7%
Adenitis 85.0%
Aphthous Stomatitis 71.2%
Headaches 30.0%
Digestive:
• Nausea 6.25%
• Vomiting 20.0%
• Abdominal pain 48.7%
• Diarrhea 22.5%
• Hepatomegaly 1.2%
• Splenomegaly 7.5%
Arthralgia 33.7%
Arthritis 1.2%
General malaise 37.5%
Skin rash 21.2%
Conjunctivitis 8.7%
Myalgia 26.2%
Neurological symptoms
(febrile seizure, one encephalitis)
5%
Acute scrotum 1.2%
Peritonitis 0%
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different reasons. First of all, the elaboration of the new
criteria was not the result of a statistical multivariate
analysis of real patients with different confounding con-
ditions (i.e. other autoinflammatory diseases, cyclic neu-
tropenia or recurrent infections), but was made on the
unique judgment of a panel of experts after the indica-
tions coming from a larger Delphi survey. The lack of a
control group didn’t allow us to calculate specificity and
sensitivity of the new criteria. Moreover, the evaluation
of the new criteria was done retrospectively on a cohort of
only 80 patients with the diagnosis of PFAPA coming from
only two centers, for which the diagnosis was based on
the judgments of each center, not on the basis of a con-
sensus among different experts.
This was the first attempt to create a new set of classifica-
tion criteria for PFAPA syndrome based on a consensus
among experts. With its limitations, this study allowed us
to identify difficulties hidden in a consensus-based process,
underlying the need for a definition of gold standard
PFAPA patients to develop validated classification criteria,
and paving the way for a better-structured project that is
ongoing.
Conclusions
Our work led us to identify a new set of classification cri-
teria for PFAPA syndrome that resulted to be too restrictive
to be applied in daily clinical practice for the diagnosis of
PFAPA. A new attempt, based on consensus among experts
followed by evaluation and validation of the criteria on a
cohort of gold standard patients is required, to define a set
of classification criteria for PFAPA syndrome with a better
performance in term of sensitivity and specificity.
Abbreviation
PFAPA: Periodic fever aphthous stomatitis pharyngitis cervical adenitis
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